PMID- 24991787 OWN - NLM STAT- MEDLINE DCOM- 20151030 LR - 20140827 IS - 1879-0712 (Electronic) IS - 0014-2999 (Linking) VI - 740 DP - 2014 Oct 5 TI - Circulating monocyte chemotactic protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1) and angiogenin in type 2 diabetic patients treated with statins in low doses. PG - 474-9 LID - S0014-2999(14)00492-0 [pii] LID - 10.1016/j.ejphar.2014.06.041 [doi] AB - Statins are known as agents promoting a biphasic dose-dependent effect on angiogenesis under experimental conditions. Dysregulation of angiogenesis plays an important role in the development of atherosclerosis and it may be affected by metabolic factors. The aim of this research was to explain how low doses of statins modify serum concentrations of pro-angiogenic factors MCP-1 and angiogenin in type 2 diabetic patients. Measurements of metabolic control parameters were performed in 30 patients with type 2 diabetes treated with low doses of statin, and in 34 statin-free patients with type 2 diabetes. The serum levels of MCP-1 and VCAM-1 in statin-treated patients were lower than those of the statin-free group. ANCOVA results revealed that these effects were dependent only on the use of statins. In type 2 diabetic subjects, overall positive correlation was found between total cholesterol or LDL serum concentration and MCP-1 serum level. The angiogenin concentration in the serum did not show differences and was comparable in both groups. The angiogenin serum level correlated negatively with HDL, LDL and with HbA1c. Multivariate regression analysis indicated that angiogenin serum levels in type 2 diabetic patients were determined mainly by HbA1c, HDL-cholesterol and diabetes duration. It has been shown that statins used in low doses in type 2 diabetic subjects decrease MCP-1 and VCAM-1serum levels, most likely due to the statins-related effect on the lipid profile, while angiogenin serum levels in this group are determined rather by the current metabolic control. CI - Copyright (c) 2014 Elsevier B.V. All rights reserved. FAU - Dworacka, Marzena AU - Dworacka M AD - Department of Pharmacology Poznan University of Medical Sciences, Rokietnicka 5a, 60-805 Poznan, Poland. Electronic address: mdworac@ump.edu.pl. FAU - Krzyzagorska, Ewa AU - Krzyzagorska E AD - Poznan Specialist Center of Medical Care, Diabetology Out-patient Clinic, Poznan, Poland. Electronic address: Ewa.Krzyzagorska@cs.put.poznan.pl. FAU - Wesolowska, Anna AU - Wesolowska A AD - Department of Pharmacology Poznan University of Medical Sciences, Rokietnicka 5a, 60-805 Poznan, Poland. Electronic address: wesolowska_a@o2.pl. FAU - Zharmakhanova, Gulmira AU - Zharmakhanova G AD - Department of Pharmacology, West Kazakhstan State Medical University, Maresev str. 68, Aktobe, Kazakhstan. Electronic address: gmzh@list.ru. FAU - Iskakova, Saule AU - Iskakova S AD - Department of Pharmacology, West Kazakhstan State Medical University, Maresev str. 68, Aktobe, Kazakhstan. Electronic address: saule1@inbox.ru. FAU - Dworacki, Grzegorz AU - Dworacki G AD - Department of Clinical Immunology Poznan University of Medical Sciences, Rokietnicka 5d, 60-805 Poznan, Poland. Electronic address: gdwrck@ump.edu.pl. LA - eng PT - Controlled Clinical Trial PT - Journal Article DEP - 20140630 PL - Netherlands TA - Eur J Pharmacol JT - European journal of pharmacology JID - 1254354 RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Hypoglycemic Agents) RN - 0 (Vascular Cell Adhesion Molecule-1) RN - 97C5T2UQ7J (Cholesterol) RN - EC 3.1.27.- (angiogenin) RN - EC 3.1.27.5 (Ribonuclease, Pancreatic) SB - IM MH - Aged MH - Chemokine CCL2/*blood MH - Cholesterol/blood MH - Diabetes Mellitus, Type 2/*blood/drug therapy MH - Female MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use MH - Hypoglycemic Agents/pharmacology/therapeutic use MH - Male MH - Middle Aged MH - Ribonuclease, Pancreatic/*blood MH - Vascular Cell Adhesion Molecule-1/*blood OTO - NOTNLM OT - Angiogenesis OT - Angiogenin OT - MCP-1 OT - Statins OT - Type 2 diabetes OT - VCAM-1 EDAT- 2014/07/06 06:00 MHDA- 2015/10/31 06:00 CRDT- 2014/07/04 06:00 PHST- 2014/02/26 00:00 [received] PHST- 2014/06/19 00:00 [revised] PHST- 2014/06/20 00:00 [accepted] PHST- 2014/07/04 06:00 [entrez] PHST- 2014/07/06 06:00 [pubmed] PHST- 2015/10/31 06:00 [medline] AID - S0014-2999(14)00492-0 [pii] AID - 10.1016/j.ejphar.2014.06.041 [doi] PST - ppublish SO - Eur J Pharmacol. 2014 Oct 5;740:474-9. doi: 10.1016/j.ejphar.2014.06.041. Epub 2014 Jun 30.